Long-term Safety Extension to Study TRCA-301

Metabolic Acidosis Clinical Trial

Official title:

A Blinded, Placebo-Controlled Extension to Study TRCA-301 to Evaluate the Long-term Safety and Durability of Effect of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03390842
• Other study ID #: TRCA-301E
• Status: Completed
• Phase: Phase 3
• Start date: December 20, 2017
• Est. completion date: February 22, 2019

Study information

• Verified date: September 2021
• Source: Tricida, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a 40-week, blinded, placebo-controlled extension of Study TRCA-301 (NCT03317444). Eligible subjects who complete the 12-week treatment period in Study TRCA-301 have the option to participate in this extension study evaluating the long-term safety and durability of effect of TRC101 in subjects with non-dialysis dependent chronic kidney disease and metabolic acidosis. Eligible subjects will be treated with TRC101 or placebo once daily (QD) on an out-patient basis for the subsequent 40 weeks. Subjects will continue to receive the same blinded treatment (TRC101 or placebo) that they received in Study TRCA-301.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 196
• Est. completion date: February 22, 2019
• Est. primary completion date: February 22, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Key Inclusion Criteria:

• Completed the 12-week treatment period and attended the Week 12 Visit in the parent study TRCA-301.
• Blood bicarbonate level of >= 12 mEq/L at the Week 12 Visit in the parent study TRCA-301.

Key Exclusion Criteria:

• Any level of low blood bicarbonate at the Week 12 Visit that, in the opinion of the Investigator, requires emergency intervention or evaluation for an acute acidotic process.
• Required dialysis for acute kidney injury or worsening CKD during the parent study TRCA-301.
• Planned initiation of renal replacement therapy within 6 months following study entry.
• History or current diagnosis of diabetic gastroparesis, bowel obstruction, swallowing disorders, severe gastrointestinal disorders, inflammatory bowel disease, major gastrointestinal surgery, or active gastric/duodenal ulcers.
• Serum calcium <= 8.0 mg/dL at the Week 10 in the parent study TRCA-301.

Related Conditions & MeSH terms

• Acidosis
• Metabolic Acidosis

Intervention

Drug:
• TRC101
Oral suspension
• Placebo
Oral suspension

Locations

Country	Name	City	State
Bulgaria	Investigative Site 11	Sofia
Georgia	Investigative Site 31	Tbilisi
Georgia	Investigative Site 32	Tbilisi
Georgia	Investigative Site 33	Tbilisi
Georgia	Investigative Site 34	Tbilisi
Georgia	Investigative Site 35	Tbilisi
Georgia	Investigative Site 36	Tbilisi
Georgia	Investigative Site 37	Tbilisi
Hungary	Investigative Site 41	Budapest
Hungary	Investigative Site 46	Budapest
Hungary	Investigative Site 49	Hódmezovásárhely
Hungary	Investigative Site 44	Kistarcsa
Serbia	Investigative Site 61	Vršac
Slovenia	Investigative Site 72	Jesenice
Slovenia	Investigative Site 71	Maribor
Ukraine	Investigative Site 81	Kharkiv
Ukraine	Investigative Site 83	Kharkiv
Ukraine	Investigative Site 87	Kharkiv
Ukraine	Investigative Site 88	Kharkiv
Ukraine	Investigative Site 84	Kyiv
Ukraine	Investigative Site 85	Kyiv
Ukraine	Investigative Site 86	Kyiv
United States	Investigative Site 95	Atlanta	Georgia
United States	Investigative Site 59	Hialeah	Florida
United States	Investigative Site 93	Hollywood	Florida
United States	Investigative Site 92	Lauderdale Lakes	Florida
United States	Investigative Site 91	Los Angeles	California
United States	Investigative Site 55	Phoenix	Arizona
United States	Investigative Site 52	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Tricida, Inc.

Countries where clinical trial is conducted

United States,  Bulgaria,  Georgia,  Hungary,  Serbia,  Slovenia,  Ukraine, 

References & Publications (1)

Wesson DE, Mathur V, Tangri N, Stasiv Y, Parsell D, Li E, Klaerner G, Bushinsky DA. Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week e — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Adverse Events, Serious Adverse Events, and Adverse Events Leading to Withdrawal.	The incidence of adverse events (AEs), serious adverse events (SAEs) and AEs leading to withdrawal. For incidence of AEs and SAEs, see Adverse Events Section. For incidence of AEs leading to withdrawal, see endpoint values below.	Week 12 Visit in the parent study, TRCA-301, to the Week 54 Visit in the extension study, TRCA-301E.
Secondary	Subjects With Change From Baseline in Serum Bicarbonate of = 4 mEq/L or Serum Bicarbonate Within the Normal Range	Percent of subjects having a change from baseline in serum bicarbonate of at least 4 mEq/L or bicarbonate in the normal range (22 - 29 mEq/L) at the end of treatment (Week 52).	Baseline in the parent study, TRCA-301, to the Week 52 Visit in the extension study, TRCA-301E.
Secondary	Change From Baseline in Serum Bicarbonate at the End of Treatment	Change from baseline in serum bicarbonate at the end of treatment (Week 52).	Baseline in the parent study, TRCA-301, to the Week 52 Visit in the extension study, TRCA-301E.
Secondary	Change From Baseline in the Total Score of the KDQOL-PFD at the End of Treatment	Change from baseline in the total score of the Kidney Disease Quality of Life Physical Function Domain (KDQOL-PFD) at the end of treatment. The KDQOL is a validated, kidney disease-specific measure of health-related quality of life. For study TRCA-301E, and the parent study TRCA-301, the 10-question Item 3 of the KDQOL, also known as the SF-36 Physical Function subscale, was selected to measure physical functioning and is referenced herein as the KDQOL-PFD. The KDQOL-PFD was chosen as a patient-reported outcome measurement to evaluate the effects of TRC101 on daily activities that may be adversely affected by loss of muscle caused by metabolic acidosis. The minimum score for each of the 10 questions is 0 (physical activity highly limited) and the maximum is 100 (physical activity not limited). The total KDQOL-PFD score is calculated by adding the scores for all 10 questions, for a minimum and maximum possible total KDQOL-PFD score of 0 or 100, respectively.	Baseline in the parent study, TRCA-301, to the Week 52 Visit in the extension study, TRCA-301E.
Secondary	Change From Baseline in the Duration of Repeated Chair Stand Test at the End of Treatment	Change from baseline in the duration of repeated chair stand test at the end of treatment (Week 52). The five-times repeated chair stand test was used as a measure of lower extremity muscle strength. In this test, the time it took for a subject to repeatedly stand from a chair five times was recorded. This test is among the group of measures (gait speed, chair stand, and balance tests) comprising the Short Physical Performance Battery (SPPB), which has been used as a predictive tool for possible disability and for monitoring physical functioning in older people.	Baseline in the parent study, TRCA-301, to the Week 52 Visit in the extension study, TRCA-301E.